Polaryx Therapeutics, Inc. — Form 8-K
Filed July 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Polaryx filed an 8-K on 2026-07-21 reporting Item 5.02 (departure of directors/officers and compensatory arrangements). The filing indicates changes in officer or director status and related compensation terms as of 2026-07-19, but the specific names, titles, dollar amounts, share grants, severance terms, and departure reasons are not disclosed in the header metadata provided. The actual substantive terms must be in the 8-K document body (not excerpted here).
Why this rating
Standard officer/director change disclosure. No concrete dollar impact quantified in available text; significance capped by company's $3.5M asset base and routine nature of such filings absent material severance or equity grants disclosed.
Extracted items
See more from July 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.